Is MET p.Ala361Pro (c.1081G>C) pathogenic?

MET p.Ala361Pro (c.1081G>C) is classified Uncertain significance in MET (ClinVar, Single submitter, 1 submitter; last evaluated 2019-02-08). AlphaMissense: likely pathogenic (0.9856); Absent from gnomAD v4.1; Associated with renal cell carcinoma.

What condition is associated with MET p.Ala361Pro (c.1081G>C)?

MET p.Ala361Pro (c.1081G>C) is associated with renal cell carcinoma (ClinVar).

How common is MET p.Ala361Pro (c.1081G>C) in the general population?

MET p.Ala361Pro (c.1081G>C) is absent from gnomAD v4.1 (gnomAD).

What do computational predictors say about MET p.Ala361Pro (c.1081G>C)?

AlphaMissense predicts likely pathogenic (score 0.9856) — an in-silico prediction, not a clinical call.

MET p.Ala361Pro

c.1081G>C · rs786202310 · VCV835313

Uncertain significance Single submitter

Classification

Uncertain significance

ClinVar

Review

Single submitter ★☆☆☆

ClinVar · 1 submitter

AlphaMissense

likely pathogenic

0.9856 · ACMG-weighted

gnomAD v4.1

Absent

absent from gnomAD v4.1

Missense predictors

3/3 damaging

AlphaMissense, REVEL, SaProt

Conditions

renal cell carcinoma

Computational evidence

Protein change
AlphaMissense	0.9856	likely pathogenic · top 7% in MET
REVEL	0.664	pathogenic-leaning
SaProt	LLR -15.59	damaging
⇒ AlphaMissense, REVEL and SaProt all call this damaging.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP 12	GERP 1.9, phastCons 1
Overall
CADD	26.9	PHRED · no single calibrated threshold — expert panels disagree

ClinVar classifies this uncertain; the computational predictors unanimously lean damaging — a triage signal, not a reclassification

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene: MET
Protein: p.Ala361Pro
Coding: c.1081G>C
MANE Select: NM_000245
dbSNP: rs786202310
Type: single nucleotide variant
Location: chr7:116700165 (GRCh38)
Gene constraint: LOEUF 0.446 · pLI 1.00 (gnomAD)
Structure: AlphaFold pLDDT 79.28 · 130 PDB
Residue 361: a β-strand; the sema domain

Full MET gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

renal cell carcinoma — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

Similar variants

MET p.Ala361Thr Uncertain significance ★★ ⚠ same residue
MET p.Ala361Val Uncertain significance ★★ ⚠ same residue
MET p.Ala361= Likely benign ★★ same residue
MET p.Ala361Ser Conflicting classifications of pathogenicity ★ ⚠ same residue
MET p.His1094Arg Pathogenic/Likely pathogenic ★★ ⚠ same condition
MET p.Met1131Thr Pathogenic/Likely pathogenic ★★ same condition
MET p.Val1092Ile Pathogenic/Likely pathogenic ★★ same condition
MET p.Val1220Ile Pathogenic/Likely pathogenic ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/met-p-ala361pro (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown